or Try an Advanced Search...

    Technical Analysis for OCS - Oculis Holding AG

    Grade Last Price % Change Price Change
    C 11.89 -0.50% -0.06
    OCS closed down 0.5 percent on Monday, July 1, 2024, on 13 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical OCS trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Gapped Down Weakness 0.00%
    Crossed Above 20 DMA Bullish -0.50%
    Bollinger Band Squeeze Range Contraction -0.50%
    Gapped Up Strength -0.50%
    Fell Below 20 DMA Bearish 1.62%
    Bollinger Band Squeeze Range Contraction 1.62%
    BB Squeeze + Lower Band Touch Range Contraction 1.62%
    Outside Day Range Expansion 1.62%
    Older End-of-Day Signals for OCS ...

       Recent Intraday Alerts

    Alert Time
    Down 1% about 6 hours ago
    Fell Below 20 DMA about 6 hours ago
    Possible NR7 about 6 hours ago
    Possible Inside Day about 6 hours ago
    Rose Above 20 DMA 3 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    OCS Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Lausanne, Switzerland.
    Classification
    Sector: Financial Services
    Industry: Shell Companies
    Keywords: Medicine Biopharmaceutical Disease Organ Systems Diabetes Ophthalmology Glaucoma Diabetic Retinopathy Macular Edema Diabetic Macular Edema Blindness Retinopathy Dry Eye Disease Ophthalmic Diseases

    Is OCS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 11 Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
    Jun 10 Oculis sees promising topline phase 2 results for licaminlimab for dry eye
    Jun 10 Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
    May 30 Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
    May 23 While institutions own 39% of Oculis Holding AG (NASDAQ:OCS), individual investors are its largest shareholders with 55% ownership
    May 9 Oculis Holding reports Q1 results
    May 8 Oculis Reports Q1 2024 Financial Results and Provides Company Updates
    May 8 Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
    Apr 29 Oculis Publishes Invitation to the Annual General Meeting
    Apr 22 Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
    See more OCS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 14.495
    52 Week Low 9.05
    Average Volume 34,378
    200-Day Moving Average 11.44
    50-Day Moving Average 12.03
    20-Day Moving Average 11.83
    10-Day Moving Average 11.80
    Average True Range 0.24
    RSI (14) 50.98
    ADX 14.04
    +DI 17.62
    -DI 24.48
    Chandelier Exit (Long, 3 ATRs) 11.33
    Chandelier Exit (Short, 3 ATRs) 11.86
    Upper Bollinger Bands 12.02
    Lower Bollinger Band 11.65
    Percent B (%b) 0.66
    BandWidth 3.10
    MACD Line -0.03
    MACD Signal Line -0.05
    MACD Histogram 0.0193
    Fundamentals Value
    Market Cap 433.22 Million
    Num Shares 36.4 Million
    EPS -2.69
    Price-to-Earnings (P/E) Ratio -4.42
    Price-to-Sales 510.76
    Price-to-Book 3.79
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.19
    Resistance 3 (R3) 12.16 12.03 12.14
    Resistance 2 (R2) 12.03 11.95 12.05 12.12
    Resistance 1 (R1) 11.96 11.91 12.00 11.99 12.11
    Pivot Point 11.83 11.83 11.85 11.85 11.83
    Support 1 (S1) 11.76 11.75 11.80 11.79 11.67
    Support 2 (S2) 11.63 11.71 11.65 11.66
    Support 3 (S3) 11.56 11.63 11.64
    Support 4 (S4) 11.59